Literature DB >> 22029544

Regional variability in symptom-based MELD exceptions: a response to organ shortage?

C K Argo1, G J Stukenborg, T M Schmitt, S C Kumer, C L Berg, P G Northup.   

Abstract

MELD (model for end-stage liver disease) exception awards affect the liver allocation process. Award rates of specific nonhepatocellular carcinoma exceptions, termed symptom-based exceptions (SBE), differ across UNOS regions. We aimed to characterize the regional variability in SBE awards and examine predictive factors for receiving a SBE in the MELD era. The OPTN liver transplant and waiting list dataset was analyzed for waiting list registrants during the MELD allocation on February 27, 2002, until November 22, 2006. Competing risks proportional hazards regression analysis was used to examine predictors for receiving a SBE in 39 169 registrants. The hazard ratios for receiving a SBE differed significantly across regions when adjusted for multiple variables including age, gender, ethnicity, physiologic MELD score, blood group, functional status, etiology of liver disease, insurer and education level. Utilization of SBE is highly significantly variable across UNOS regions, and does not correlate with organ availability as estimated by the regional mean physiologic MELD score at transplantation. Patients with Medicaid as their primary payer have a lower likelihood of receiving a SBE award, while patients with cryptogenic/NASH cirrhosis or cholestatic liver disease have a higher likelihood of receiving a SBE. Reasons for these regional and demographic disparities deserve further investigation. ©Copyright 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Year:  2011        PMID: 22029544     DOI: 10.1111/j.1600-6143.2011.03738.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  6 in total

Review 1.  Strategies to optimize the use of marginal donors in liver transplantation.

Authors:  Daniele Pezzati; Davide Ghinolfi; Paolo De Simone; Emanuele Balzano; Franco Filipponi
Journal:  World J Hepatol       Date:  2015-11-18

Review 2.  Model for End-stage Liver Disease.

Authors:  Ashwani K Singal; Patrick S Kamath
Journal:  J Clin Exp Hepatol       Date:  2012-12-01

Review 3.  Liver Transplantation for Cholestatic Liver Diseases in Adults.

Authors:  Vandana Khungar; David Seth Goldberg
Journal:  Clin Liver Dis       Date:  2015-10-23       Impact factor: 6.126

4.  United Network for Organ Sharing regional variations in appeal denial rates with non-standard Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease exceptions: support for a national review board.

Authors:  Robert G Gish; Robert J Wong; Gordon Honerkamp-Smith; Ronghui Xu; Robert W Osorio
Journal:  Clin Transplant       Date:  2015-04-16       Impact factor: 2.863

Review 5.  A scoping review of inequities in access to organ transplant in the United States.

Authors:  Christine Park; Mandisa-Maia Jones; Samantha Kaplan; Felicitas L Koller; Julius M Wilder; L Ebony Boulware; Lisa M McElroy
Journal:  Int J Equity Health       Date:  2022-02-12

6.  Evaluating twenty-years of follow-up after orthotopic liver transplantation, best practice for donor-recipient matching: What can we learn from the past era?

Authors:  Niklas Buescher; Daniel Seehofer; Michael Helbig; Andreas Andreou; Marcus Bahra; Andreas Pascher; Johann Pratschke; Wenzel Schoening
Journal:  World J Transplant       Date:  2016-09-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.